Arie Belldegrun
CIK 1296549 · Chairman, President and CEO · last filed 2026-06-24
Arie Belldegrun is a Chairman, President and CEO who has filed 75 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for URGN, was dated Jun 24, 2026. Across all open-market trades the lifetime net is +$14.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $18.8M across reported positions. 2 SEC filings were submitted jointly with Vida Ventures GP III, L.L.C.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALLO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
10833 LE CONTE 66-118 CHS BOX 951738
LOS ANGELES, CA 9095-1738
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| URGN | Director | 408,693 | $34.04 | $13.91M | $0 | 13 | 2026-06-24 |
| ALLO | Director | 4,034,979 | $1.21 | $4.88M | $17.96M | 18 | 2026-02-04 |
| Kronos Bio, Inc. (KRON) Delisted | Director | 0 | $0.88 | $0 | $0 | 6 | 2025-06-20 |
| Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Director | 694,925 | $0.01 | $4.4K | $0 | 3 | 2024-06-14 |
| Kite Pharma, Inc. (KITE) Delisted | Chairman, President and CEO | 609,160 | — | — | -$3.75M | 7 | 2017-09-27 |
| CAPRICOR THERAPEUTICS, INC. (NLTXW) Delisted | Director | 292,000 | — | — | $0 | 2 | 2011-05-12 |
| CAPRICOR THERAPEUTICS, INC. (NLTX) Delisted | Director | 65 | $13.96 | $907 | $0 | 1 | 2009-09-28 |
| Cougar Biotechnology, Inc. (CGRB) Delisted | Director | 0 | — | — | $727.5K | 5 | 2009-07-07 |
| Talon Therapeutics, Inc. (HNAB) Delisted | Director | 0 | — | — | $0 | 2 | 2009-02-26 |
Recent Filings
75 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-24 | URGN | Grant (A) | — | $0 | EDGAR |
| 2026-02-04 | ALLO | Grant (A) | — | $0 | EDGAR |
| 2025-08-27 | URGN | Grant (A) | — | $0 | EDGAR |
| 2025-06-20 | Kronos Bio, Inc. (KRON) Delisted | Mixed | −3,444,889 | -$1.96M | EDGAR |
| 2025-01-28 | ALLO | Grant (A) | +369,957 | $0 | EDGAR |
| 2024-08-08 | URGN | Grant (A) | — | $0 | EDGAR |
| 2024-06-26 | Kronos Bio, Inc. (KRON) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Mixed | +105,263 | $0 | EDGAR |
| 2024-05-20 | ALLO | Mixed | +2,068,965 | $6.00M | EDGAR |
| 2024-01-31 | ALLO | Grant (A) | +211,973 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.